RECBIO-B News

CMB International: The target price for the “buy” rating for Ricoh Bio-B (02179) was lowered to HK$20.96

Zhitong FinanceMay 30, 2023 11:25

Ricoh Bio-B (02179.HK): Vaccine BIOTECH developed independently as the core driving force

中信證券Jan 6, 2023 18:16

CMB International: Maintaining the target price of Ricoh Bio-B (02179) “Buy” rating at HK$38.86

Zhitong FinanceDec 20, 2022 15:33

Ricoh Biotech (2179.HK): COVID-19 vaccine RECOV is clinically approved for clinical trial over Pfizer's MRNA vaccine neutralizing antibodies

海通國際Dec 19, 2022 00:00

Ricoh Biology-B (02179.HK): R&D expenditure is increasing rapidly, pipeline progress is progressing smoothly

國金證券Sep 26, 2022 00:00

Ricoh Biology-B (02179.HK): Promoting the gradual implementation of production capacity construction in an orderly manner in research pipelines

興業證券Sep 15, 2022 13:11

Ricoh Bio-B (02179.HK): A rising star of domestic vaccines that are deeply involved in protein engineering+novel adjuvants

興業證券Jun 1, 2022 19:51

Ricoh Biotech (02179.HK): Leading adjuvant platform to build a rich pipeline of novel vaccines under development

華安證券May 30, 2022 00:00

Ricoh Biology-B (02179.HK): Leading the Vaccine, Novel Adjuvant Vaccine Pipeline Layout Is Important

國金證券May 24, 2022 00:00

Ricoh Biology-B (02179.HK): Innovative domestic vaccines, new and novel adjuvants boost industrial upgrading

廣發證券May 9, 2022 00:00

New share News: Jiangsu Ruike Biotechnology Co., Ltd.-B (2179.HK)

致富證券Mar 21, 2022 00:00